"Arsenicals" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inorganic or organic compounds that contain arsenic.
| Descriptor ID |
D001152
|
| MeSH Number(s) |
D01.075 D02.691.088
|
| Concept/Terms |
Arsenicals- Arsenicals
- Arsenic Compounds
- Compounds, Arsenic
|
Below are MeSH descriptors whose meaning is more general than "Arsenicals".
Below are MeSH descriptors whose meaning is more specific than "Arsenicals".
This graph shows the total number of publications written about "Arsenicals" by people in this website by year, and whether "Arsenicals" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 1 | 1 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Arsenicals" by people in Profiles.
-
Micro-CT imaging of multiple K-edge elements using GaAs and CdTe photon counting detectors. Phys Med Biol. 2023 04 12; 68(8).
-
Serum homocysteine, arsenic methylation, and arsenic-induced skin lesion incidence in Bangladesh: A one-carbon metabolism candidate gene study. Environ Int. 2018 04; 113:133-142.
-
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 2015 Mar; 168(5):646-53.
-
Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. Cancer. 2012 Dec 01; 118(23):5811-8.
-
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer. 2012 May 01; 118(9):2507-15.
-
Acute promyelocytic leukemia can be treated successfully without cytotoxic chemotherapy. Oncology (Williston Park). 2011 Jul; 25(8):741-3.
-
Therapy-related acute promyelocytic leukemia. Haematologica. 2011 Apr; 96(4):493-5.
-
Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy. Clin Lymphoma Myeloma Leuk. 2010 Oct; 10 Suppl 3:S122-6.
-
Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer. 2011 Jan 01; 117(1):110-5.
-
Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Int J Cancer. 2009 Jul 15; 125(2):264-75.